Validation of chromatographic method for impurity profiling of Baloxavir marboxil (Xofluza)
Baloxavir marboxil (BXM) is a new antiviral drug that inhibits the cap-dependent endonuclease required to replicate the virus. The efficacy, quality, and safety of drug products and active pharmaceutical ingredients (APIs) may be compromised by impurities. To ensure the safety and quality of medicat...
Saved in:
| Main Authors: | Wang Yiyun, Wang Zhiping, Wu Hui, Meng Zihui, Zheng Zhonghui, Li Jiarong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2025-03-01
|
| Series: | Science and Engineering of Composite Materials |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/secm-2022-0228 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical efficacy of baloxavir marboxil versus oseltamivir in kidney transplant recipients with influenza
by: Jiali Jiang, et al.
Published: (2025-07-01) -
Safety evaluation of baloxavir marboxil: analysis and discussion utilizing real adverse events from the FAERS database
by: Xiaolong Lai, et al.
Published: (2025-05-01) -
Ultrasensitive turn-off fluorescent sensor for estimation of the new influenza antiviral prodrug baloxavir marboxil in its pharmaceutical formulation
by: Amira S. Gouda, et al.
Published: (2025-01-01) -
Influenza A(H1N1)pdm09 Virus with Reduced Susceptibility to Baloxavir, Japan, 2024
by: Emi Takashita, et al.
Published: (2025-05-01) -
Influenza: state-of-the-art and vaccination during COVID-19 pandemic
by: Editorial Article
Published: (2021-06-01)